Earnings call briefFiscal fourth-quarter 2026

Twist Bioscience TWST

Twist Bioscience sees potential for triple-digit AI order growth in fiscal 2027

CFO Adam Laponis said he expects fiscal 2027 gross margin to still expand, despite about $15 million a year of depreciation, or about 2 to 3 points of headwind.

GetSignal 

Share
Download on the App StoreGet it on Google Play

Free on iOS and Android

On its fiscal fourth-quarter call, Twist Bioscience said its initial fiscal 2027 guidance assumes $100 million in AI drug discovery revenue, from programs it can forecast with high confidence. It said additional programs with existing and new customers are not fully reflected in that guidance.

Laponis said the company expects approximately $150 million in capital expenditures for capacity, automation and software over fiscal 2027 and fiscal 2028, plus more than $30 million in landlord-funded tenant improvements.

Quotes from the call

“Over fiscal 2027 and fiscal 2028, we expect approximately $150 million in capital expenditures for capacity, automation and software, plus more than $30 million in landlord-funded tenant improvements.”

Adam Laponis, CFO

Key facts from the call

Expected fiscal 2027 AI drug discovery revenue assumption
$100 million, from programs it can forecast with high confidence
Expected fiscal 2027 and fiscal 2028 capital expenditures
approximately $150 million for capacity, automation and software, plus more than $30 million in landlord-funded tenant improvements
Expected fiscal 2027 depreciation on capital spending of about $75 million
approximately $15 million a year

All TWST call briefs

Source: Twist Bioscience's fiscal fourth-quarter 2026 earnings call, November 12, 2026.

Written by GetSignal with AI from the company's earnings call. How we make news

Not investment advice.

More earnings call briefs

The newest

All earnings call briefs